# US 2025/0084081 A1 · Compounds for targeted degradation of brd9

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084081 A1
- Document ID: US20250084081A1
- Status: Published application
- Kind: A1
- Application number: 18/945,284
- Filed: 2024-11-12
- Published: 2025-03-13
- Earliest claimed: 2020-03-05
- Assignees: C4 Therapeutics, Inc.
- Applicants: C4 Therapeutics, Inc.
- Inventors: Christopher G. Nasveschuk; Rhamy Zeid; Ning Yin; Katrina L. Jackson; Gesine Kerstin Veits; Moses Moustakim; Jeremy L. Yap
- Web page: https://patentgrep.com/patent/US20250084081A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 487/08: Bridged systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

## Claims

### Claim 1

A compound selected from the group consisting of Formula I, Formula II, Formula III, Formula IV, Formula V, and Formula VI:
or a pharmaceutically acceptable salt thereof;
wherein:
each a is independently 0, 1, or 2;
each y is independently 0, 1, or 2;
X3, X4, X5, and X6 are selected from the group consisting of N, CH and CR3, wherein no more than 3 of X3, X4, X5, and X6 are N;
X7 is N or CH;
X8 and X9 are each independently at each occurrence selected from the group consisting of N and CH; wherein at least one of X8 or X9 is CH;
X12 is a 5-membered heteroaryl group with 1, 2, or 3 atoms independently selected from the group consisting of N, O, and S, wherein X12 is optionally substituted with 1, 2, or 3 groups independently selected from R3;
X17 is aryl, heteroaryl, bicycle, or cycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R3;
Q1 is independently at each occurrence selected from the group consisting of NH, N(alkyl), N(haloalkyl), CH2, O, and S; wherein if X7 is N, then Q1 is CH2;
R is independently at each occurrence selected from the group consisting of hydrogen, C1-C4 haloalkyl, C1-C4alkyl, fluorine, chlorine, bromine, iodine, CH2F, CHF2, CF3, CH2Cl, CHCl2, CCl3, CH2Br, CHBr2, and CBr3;
R1 is hydrogen, C1-C4alkyl, C1-C4 haloalkyl, or cycloalkyl;
R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, alkoxy, C1-C4alkyl, C1-C4 haloalkyl, cycloalkyl, fluorine, chlorine, bromine, and iodine;
B is selected from B1 and B2;
B1 is selected from the group consisting of:
B2 is selected from the group consisting of:
X10 is C(R7)2, C(O), or O;
X11 is heterocycle, heteroaryl, aryl, cycloalkyl, or a bicycle, each of which X11 groups is optionally substituted with 1, 2, 3, or 4 groups independently selected from R3;
or X10 and X11 are taken together to form
X13, X14, X15, and X16 are independently selected from the group consisting of N, CH, and CR4, wherein no more than 3 of X13, X14, X15, and X16 are N;
each R4 is independently selected from the group consisting of hydrogen, aryl, heteroaryl, C1-C4alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C1-C4alkyl, fluorine, chlorine, bromine, and iodine;
wherein two R4 groups on adjacent carbon atoms may optionally combine to form a fused cycle, wherein the fused cycle is optionally substituted with 1, 2, or 3 R substituents;
R5 is hydrogen, C1-C4alkyl, allyl, crotyl, alkenyl, alkynyl, haloalkyl, or cycloalkyl;
each R6 is independently selected from the group consisting of hydrogen, C1-C4alkoxy, C1-C4alkyl, C1-C4 haloalkyl, fluorine, chlorine, bromine, and iodine;
each R7 is independently hydrogen or C1-C4alkyl;
R8 is hydrogen, C1-C4alkyl, allyl, crotyl, alkenyl, alkynyl, haloalkyl, or cycloalkyl;
L is a bivalent Linker of formula:
wherein:
X1 and X2 are independently at each occurrence selected from the group consisting of bond, heterocycle, NR2, C(R2)2, O, C(O), and S;
R2 is independently at each occurrence selected from the group consisting of hydrogen, alkyl, heterocycle, aryl, heteroaryl, —C(O)H, —C(O)OH, —C(O)alkyl, —C(O)Oalkyl, —C(O)(aryl or heteroaryl), —C(O)O(aryl or heteroaryl), alkene, and alkyne;
R20, R21, R22, R23, and R24 are independently at each occurrence selected from the group consisting of a bond, alkyl, —C(O)—, —C(O)O—, —OC(O)—, —SO2—, —S(O)—, —C(S)—, —C(O)NR2—, —NR2C(O)—, —O—, —S—, —NR2—, —C(R40R40)—, —P(O)(OR26)O—, —P(O)(OR26)—, bicycle, alkene, alkyne, haloalkyl, alkoxy, aryl, heterocycle, heteroaryl, lactic acid, glycolic acid, and carbocycle; each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R40;
R26 is independently at each occurrence selected from the group consisting of hydrogen, alkyl, arylalkyl, heteroarylalkyl, alkene, alkyne, aryl, heteroaryl, and heterocycle; and
R40 is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkene, alkyne, fluoro, bromo, chloro, hydroxyl, alkoxy, azide, amino, cyano, —NH(alkyl), —N(alkyl)2, —NHSO2 (alkyl), —N(alkyl)SO2 alkyl, —NHSO2 (aryl, heteroaryl or heterocycle), —N(alkyl)SO2 (aryl, heteroaryl or heterocycle), —NHSO2 alkenyl, —N(alkyl)SO2 alkenyl, —NHSO2 alkynyl, —N(alkyl)SO2 alkynyl, haloalkyl, aryl, heteroaryl, heterocycle, and cycloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Q1 is NH and X7 is CH.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Q1 is O and X7 is CH.

### Claim 4 (depends on 1)

The compound of claim 1, wherein Q1 is N(CH3) and X7 is CH.

### Claim 5 (depends on 1)

The compound of claim 1 of Formula I:
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The compound of claim 5, wherein X8 is N and X9 is CH.

### Claim 7 (depends on 5)

The compound of claim 5, wherein X8 is CH and X9 is N.

### Claim 8 (depends on 5)

The compound of claim 5, wherein each a is 1.

### Claim 9 (depends on 1)

The compound of claim 1 of Formula II:
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R1 is CH3.

### Claim 11 (depends on 9)

The compound of claim 9, wherein X4 and X6 is CH.

### Claim 12 (depends on 1)

The compound of claim 1 of Formula III:
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The compound of claim 1 of Formula IV:
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The compound of claim 1 of Formula V:
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The compound of claim 1 of Formula VI:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The compound of claim 15, wherein Q1 is NH and X7 is CH.

### Claim 17 (depends on 1)

The compound of claim 1, wherein L is the Linker of formula:

### Claim 18 (depends on 17)

The compound of claim 17, wherein L is the Linker of formula:

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 20 (depends on 1)

A method of treating a disorder mediated by BRD9, wherein the method comprises administering an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a human patient in need thereof.
